Free tool
FAERS Monitor: Licart
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206976 or its brand name (Licart, Diclofenac Epolamine). Reports on generic versions are filed under their own applications.
Reports
701
Serious
264
38% of reports
Hospitalization
94
Death reported
32
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity183
- drug ineffective105
- pain53
- off label use41
- congenital anomaly34
- fatigue33
- malaise30
- headache29
- diarrhoea28
- dyspnoea28
- foetal exposure during pregnancy26
- nasopharyngitis26
- nausea26
- abdominal discomfort25
- pruritus24
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 21 |
| 2013 | 20 |
| 2014 | 26 |
| 2015 | 38 |
| 2016 | 27 |
| 2017 | 26 |
| 2018 | 66 |
| 2019 | 103 |
| 2020 | 72 |
| 2021 | 58 |
| 2022 | 57 |
| 2023 | 36 |
| 2024 | 43 |
| 2025 | 71 |
| 2026 | 32 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,458 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| congenital anomalySignal | 34 | 132.4 | 95.3 | 4,285 |
| drug hypersensitivitySignal | 183 | 28.4 | 25.1 | 4,850 |
| foetal exposure during pregnancySignal | 26 | 9.6 | 6.6 | 192 |
| abdominal discomfortSignal | 25 | 4.5 | 3.0 | 64 |
| nasopharyngitisSignal | 26 | 4.2 | 2.9 | 62 |
| painSignal | 53 | 2.6 | 2.0 | 52 |
| drug ineffectiveSignal | 105 | 2.4 | 2.0 | 89 |
| malaiseSignal | 30 | 2.1 | 1.4 | 15 |
| pruritus | 24 | 1.9 | 1.3 | 9 |
| dyspnoea | 28 | 1.5 | 1.0 | 4 |
| off label use | 41 | 1.4 | 1.0 | 5 |
| headache | 29 | 1.4 | 1.0 | 3 |
| diarrhoea | 28 | 1.3 | 0.9 | 2 |
| fatigue | 33 | 1.3 | 0.9 | 2 |
| nausea | 26 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.